Physician profile
Daniel D Rhoads
NPI 1386033561
$9,084.85
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $653 · 2021: $2,720 · 2022: $2,093 · 2023: $3,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Luminex Corporation | $4,800.00 | 2022-2023 | |
| Roche Diagnostics Corporation | $1,520.00 | 2021 | |
| Life Technologies Corporation | $1,200.00 | 2021 | |
| Cepheid | $792.80 | 2022 | |
| Becton, Dickinson and Company | $631.52 | 2020 | |
| Merck Sharp & Dohme LLC | $78.92 | 2019 | |
| Melinta Therapeutics, LLC | $45.86 | 2019-2020 | |
| Viiv Healthcare Company | $15.75 | 2019 |
6 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Rhoads listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.